AI-generated summary
The authors report a case of a 61-year-old man with iris neovascularization (rubeosis iridis) from proliferative diabetic retinopathy who received a single intravitreal aflibercept injection. The abstract reports that the iris neovascularization disappeared the next day and did not recur over three months of follow-up, though this is a single case report. The authors suggest aflibercept may be another anti-VEGF option for this condition.
- Participants
- 1
- Who or what was studied
- One 61-year-old man with rubeosis iridis secondary to proliferative diabetic retinopathy in one eye
- Limits stated in the abstract
- This is a single case report with only three months of follow-up, so no general conclusion about effectiveness can be drawn from the abstract.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on pubmed.ncbi.nlm.nih.gov.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.